3D Printed Bioscaffolds for Developing Tissue-Engineered Constructs by Chowdhury, Shiplu Roy et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books






3D Printed Bioscaffolds for 
Developing Tissue-Engineered 
Constructs
Shiplu Roy Chowdhury, Yogeswaran Lokanathan, 
Law Jia Xian, Fauzi Mh Busra, Muhammad Dain Yazid, 
Nadiah Sulaiman, Gargy Lahiry and Md Enamul Hoque
Abstract
Tissue engineering techniques enable the fabrication of tissue substitutes 
integrating cells, biomaterials, and bioactive compounds to replace or repair dam-
aged or diseased tissues. Despite the early success, current technology is unable 
to fabricate reproducible tissue-engineered constructs with the structural and 
functional similarity of the native tissue. The recent development of 3D printing 
technology empowers the opportunities of developing biofunctional complex tissue 
substitutes via layer-by-layer fabrication of cell(s), biomaterial(s), and bioactive 
compound(s) in precision. In this chapter, the current development of fabricat-
ing tissue-engineered constructs using 3D bioprinting technology for potential 
biomedical applications such as tissue replacement therapy, personalized therapy, 
and in vitro 3D modeling for drug discovery will be discussed. The current chal-
lenges, limitations, and role of stakeholders to grasp the future success also will be 
highlighted.
Keywords: 3D printing, scaffold, drug delivery, regenerative medicine, tissue 
engineering
1. Introduction
3D printing is a process whereby a real object is created starting with a virtual 
3D digital model. It was first developed in 1986 by Hull and Lewis which is an 
improved stereolithography system using photochemical processes in which light 
causes chemical monomers to link together to form polymers and generate a solid 
object [1]. This technology is capable to fabricate a super complex geometry or 
features by accurately follow the computer-aided design (CAD) model. The fabrica-
tion requires appropriate materials that gradually released and overlapped in layer-
by-layer fashion by 3D printer. The type of material chosen is crucial to ensure the 
printed object that can be used for further settings and applications. Various types 
of metals, polymers, ceramics, and composites such as polycaprolactone (PCL), 
polyethylene glycol (PEG), polylactic acid (PLA), acrylonitrile butadiene styrene 
(ABS) plastic, stainless steel, titanium, calcium phosphate, and silica can be used as 
starting materials in 3D printing [2–4].
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Generally, there are four main applications of 3D printing in the medical field, 
which are as follows: (a) drug delivery, (b) surgical devices/implants, (c) operative 
planning, and (d) tissue engineering [5–12]. The 3D printing application for drug 
delivery is extensively used in the pharmaceutical industry to develop sustained 
release medication [5]. Modulation of the shell thickness as well as the shape of the 
3D printed capsule allows precise control of the drug release rate [13]. 3D printing 
enables a fast and cost-effective way of fabricating personalized medical implants. 
The capability of producing custom implants gets rid of the need for adjustments 
during surgery that saves time as well as reduces the cost of operation and the 
risk of medical complications. This is particularly beneficial where metal implant 
interfaces with living bone and tissue. The electron-beam melting (EBM) and 
direct metal laser sintering (DMLS) technologies are both now used in the produc-
tion of standard and customized implants. Surgical tools are generally designed to 
work with many patients. However, by fabricating patient-specific tools, it would 
decrease the risk of complications during surgery [13, 14]. Patient anatomy will be 
imaged using imager and transferred into the 3D design in CAD to create suitable 
tools that can be easily controlled during operation. In operative planning, the 3D 
printing also would provide surgeons with a visualization of the complex injuries. 
They can plan and strategize their work and choose specific tools required. Some 
of the common applications that require a 3D model are complex pelvic trauma 
[15], pediatric deformities [16], and osteotomies [17]. Furthermore, advances in 3D 
printing technology enable the possibilities of constructing living human tissues in 
the lab hoping to demonstrate structural and functional similarities as native tissue 
in the human body [12]. The biggest challenge is to construct thick tissue and to 
ensure the diffusion of oxygen and nutrients for cellular viability [14].
2. 3D bioprinting for designing bioscaffold
The conventional method to develop an engineered-tissue product involved the 
initial fabrication of specific native tissue design followed by the provision of cells 
and biomolecules. However, this approach could contribute to two major drawbacks 
including limitation in cell distribution and reduction in cell growth due to low 
nutrient concentration at the core area [10]. Very commonly used techniques for 
fabricating 3D scaffolds include freeze casting, solvent casting, gas foaming, and 
salt leaching [18]. The technology advancement in tissue engineering has been 
contributed to the current approach through computer-aided layered manufactur-
ing technique, which is also known as 3D bioprinting. Briefly, the 3D bioprinting 
technology involves the combination of the primary ingredients known as “bio-ink” 
that functions as a biological framework and various types of cells with the pres-
ence of chemical factors, and biomolecules to form a solid and functional in situ 3D 
living structure [19].
There are four different techniques under 3D bioprinting including inkjet 
printing, extrusion-based methods, light-induced (photopolymerization) methods 
and particle fusion-based methods [7, 20–27]. The first three abovementioned 
techniques have been widely used to fabricate biomaterial designs [7].
The inkjet-based 3D bioprinting (Figure 1), first developed by Thomas Boland 
from Clemson University in 2003, is a low-cost manufacturing process that per-
forms high-speed printing for 3D structure [21]. Besides, it provides high-resolution 
printing output up to 50 μm and widely proven to support cell viability and growth 
[22]. However, the main drawbacks are dealing with a low concentration of print-
ing ink could hamper the reliability of cell encapsulation and significantly affect 
print fidelity [23]. Besides, this approach potentially could damage the printed 
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cells on the plantar under shear stress created through the inkjet-based printing 
but no concrete evidence is reported so far [21, 24]. Three main stages could affect 
the printable ink such as the production of the droplet, droplet/substrate close-
interaction, and polymerization of the droplet. The two mechanisms, which have 
been involved under droplet generation through inkjet-based 3D bioprinting, are 
drop-on-demand and continuous inkjet [25]. The size of ink droplets produced via 
drop-on-demand and continuous injection is in the range of 25–50 and 100 μm, 
respectively [19]. Drop-on-demand inkjet has been conveniently used for tissue 
engineering applications.
The inkjet-based technology can be categorized into three as follows: thermal-
based, piezoelectric-based, and magnetic-based inkjet printing [26]. The thermal 
induction can reach until 100–300°C that is required to nucleate a bubble and 
directly increase the appropriate pressure in the printhead lead to droplet expulsion 
[28]. There is no dead effect on the cells due to the presence of high temperature 
only for a microsecond and the previous study demonstrated consistency in cell 
viability post-inkjet-based 3D bioprinting [29]. Besides, the ink drop production 
can be induced by a piezoelectric method that focuses on the pulse pressure or 
acoustic waves generated from a piezoelectric actuator to expel printing ink drop. 
Another method to generate the drop expulsion is by using the electromagnetic 
approach depending on the Lorentz force and permanent magnet-based configura-
tions. However, it produces a larger size of ink droplets as compared to thermal-
based and piezoelectric-based approaches [28].
The second approach of 3D bioprinting is the extrusion-based method (Figure 2) 
that can be divided into two types consisting of fused deposition modeling and direct 
ink writing [19]. It is easy to handle, customized-based design bioprinter, and versatile 
with the developed current system. The principle of this 3D bioprinting method is that 
the printed ink extruded from the nozzle in liquid or molten state forms a particular 
line on the platform before polymerizing [30]. The bioprinting ink is commonly in the 
form of solid coil or filament that goes through the hot nozzle (temperature of around 
200°C) before extrusion onto the platform. The extrusion from the printing nozzle is 
controlled by a specific system using various interventions including pressure-based 
control, pneumatic or mechanical control, or solenoid control before forming layered 
printed ink as required by the computerized set up to build up the 3D biomaterial 
designs [7]. The biopolymer should have an excellent solid-to-melt transition property 
to produce high-resolution 3D cell-laden on the printer platform [31]. However, the 
extrusion-based 3D bioprinting potentially could generate high mechanical force 
Figure 1. 
The inkjet-based 3D bioprinting provides high resolution of printing output around 50 μm.
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and shear stress together with high viscous of substrate lead to cellular apoptosis [5]. 
Further adjustment and optimization of this extrusion-based bioprinting can mitigate 
the drawbacks but it reduces the bioprinter resolution and speed [32]. Besides, the 
low concentration of ink viscosity supported cell proliferation and sustained the cell 
viability by introduced a composite-modified printing ink [33].
Light or laser-assisted 3D bioprinting, also known as stereolithography (SLA) 
(Figure 3), focuses on polymer resins manufacturing [19]. There are many varia-
tions of light or laser printing approaches for 3D fabrication. The advantages of 
these approaches are that they provide excellent accuracy, and good resolution 
between 10 and 50 μm [21]. This technique involves the patterning of a laser 
beam toward photo-based polymer to generate physical hardened polymer. This 
Figure 2. 
The extrusion-based 3D bioprinting is easy to handle, customized-based design bioprinter, and versatile with 
the developed current system. It can be categorized into the fused deposition modeling and direct ink writing.
Figure 3. 
Light- or laser-assisted 3D bioprinting approaches supported the high cell viability, accuracy, and good 
resolution between 10 and 50 μm. Two types consist of digital light processing-based bioprinting (DLP) and the 
two-photon polymerization-based bioprinting (TPP).
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procedure is repeatedly applied to fabricate multi-layered polymer in the build-up 
stage. The other two types of laser-assisted 3D bioprinting techniques that are pri-
marily applied in tissue engineering are digital light processing-based bioprinting 
(DLP) and the two-photon polymerization-based bioprinting (TPP) [34, 35]. The 
DLP technology uses a digitalized micro-mirror device chip (DMD) that contains 
around 2 million micro-mirrors. It functions to ensure light projection patterning 
precisely and is easy to modulate either on or off while the printing process is run-
ning on the platform. This technology consists of two 3D printing platform systems, 
namely, dynamic optical projection stereolithography (DOPS) and microscale 
continuous optical printing (μCOP) that support dynamic printing and continuous 
printing, respectively [7]. The TPP printing mechanism depends on the absorption 
of two photons by a molecule associated with light intensity square [36]. This phe-
nomenon contributed to the printing of voxel dimension below 1 μm3. Thus, this 
printing approach is an ideal method to generate nanoscale and microscale printing 
3D output. However, high-resolution printing limits the construct size and printing 
speed. Nonetheless, the TPP printing speed is still faster than that in extrusion-
based bioprinting and at a similar rate with inkjet-based bioprinting [37].
3.  3D bioprinting for developing tissue substitutes for therapeutic 
applications
Due to the limitation in technology to support the formation of the adequate and 
functional vascular network in vitro, currently, 3D bioprinting is more successful 
in the bioprinting of avascular tissue such as skin and cartilage. A complex tissue or 
organ with an extensive vascular network is still very challenging to prepare using 
the 3D bioprinting technology. To date, researchers are yet to succeed in preparing 
transplantable complex tissue or organ due to the difficulty in creating the circula-
tory system, especially the capillaries. However, several strategies have been used 
to improve the vascularization of 3D printed tissues, including printing of human 
umbilical vein endothelial cells (HUVECs) and vascular endothelial growth factors 
[38, 39] as well as seeding of endothelial cells and smooth muscle cells to the 3D 
printed tissues [40].
3.1 Bone
Bone tissue is one of the earliest tissues that were 3D printed and clinically used 
due to the ability of this technique to fabricate scaffolds according to the required 
shape, strength, and porosity. 3D printing enables fabrication of scaffold in any 
shape, which is not possible with many conventional fabrication techniques [41]. 
Furthermore, the materials commonly used for bone substitute production, such 
as hydroxylapatite (HA), synthetic calcium phosphate ceramics, polymethylmeth-
acrylate, polylactides/polyglycolide and copolymer ceramics, tricalcium phosphate 
(TCP), bioglass, titanium, and other composite materials, are very compatible with 
the 3D printing technology [42]. The bone 3D printing had started as early as the 
1990s, which utilized a powder-based freeform fabrication method [43]. Today, 
the bone substitute can be fabricated using the 3D plotting/direct ink writing, 
laser-assisted bioprinting (LAB), selective laser sintering (SLS), stereolithography 
(SLA), and fused deposition modeling (FDM) [42]. For example, Goriainov et al. 
prototyped hip joint implants using computer-aided design-computer-assisted 
manufacturing (CAD-CAM) and fabricated the scaffold using direct metal laser 
sintering from titanium alloy [44]. The custom-designed implants were seeded 
with autologous bone marrow aspirate before the implantation to 11 patients who 
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were unsuitable for standard revision hip surgery. The postoperative results showed 
extensive new bone formation in the patients and a certain level of load-bearing 
function at the hip joint. The in vitro studies demonstrated the osteogenesis of the 
skeletal stem cells and osseointegration of the cells with the titanium alloy [44].
3.2 Skin
The other tissue that has a high potential to utilize 3D printing technology to 
repair and regenerate is skin. Although skin substitutes made by conventional 
tissue engineering techniques such as Matriderm®, Integra®, Dermagraft®, and 
OrCel® have been commercialized and been used in clinics for wound treatment, 
there are still challenges that are yet to be resolved by these skin substitutes. These 
skin substitutes are expensive, require long production time with prolonged healing 
time, have limited tissue functionality, and resulted in scarring in some cases [45]. 
Besides, these skin substitutes lack hairs, sweat glands, sebaceous glands, and other 
skin appendages as well as pigmentation. The 3D bioprinting technology has led to 
the paradigm shift in the skin substitute production where this transformative tech-
nology enables simultaneous and accurate deposition of multiple types of skin cells, 
the formation of scaffolds with complex macro- and micro-architecture, creation of 
vascular networks, and construction of stratified layer [46].
The commonly used skin 3D bioprinting techniques are microextrusion, 
inkjet, stereolithography, and laser-assisted bioprinting [47]. The materials com-
monly used in skin 3D bioprinting are mainly natural polymers such as alginate, 
gelatine, collagen, fibrin, and hyaluronic acid. However, biocompatible synthetic 
materials such as polycaprolactone (PCL), polyglycolide (PGA), polyethylene 
glycol (PEG), poly(lactic-co-glycolic acid) (PLGA), and polylactide (PLA) are 
commonly combined with natural polymers to increase the mechanical strength 
of the skin substitute [46, 47]. The bio-inks serve either as the cell carrier or 
sacrificial support that is removed after the printing, or both as a carrier and 
mechanical support material that provides greater strength and microarchitec-
ture that supports the function of the skin even after the implantation on to the 
patients [46]. The on-site bioprinting of either autologous or allogeneic dermal 
fibroblasts and epidermal keratinocytes directly into a wound area is the latest 
development in skin 3D bioprinting. The direct deposition of the cells in fibrino-
gen/collagen solution in a layer-by-layer method onto porcine full-thickness 
wound has shown to promote the wound closure, reduce contraction, and 
enhance the re-epithelialization, and the regenerated skin tissue had the compo-
sition similar to healthy skin [48].
3.3 Vasculature
The other important and potential use of 3D bioprinting technology is the 
fabrication of vascularized tissues for passage of blood, air, lymph, and other vital 
fluids in the human body. The cells in dense tissue need to be within 200 mm from a 
vessel supplying oxygen and nutrients to survive [49]. The conventional technolo-
gies faced a major hindrance in fabricating vascular network structure in the dense 
engineered tissues, which is very crucial for the functioning of the implanted tissue 
or organ substitute, due to the technological limitation [50]. However, 3D bioprint-
ing technology had enabled the fabrication of complex tissues with an integrated 
vasculature system, which in turn enabled the integration of the implant vascula-
ture system with that of the host and long-term exchange of air, nutrient, and waste 
between the native and the implanted tissues [51].
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The construction of the vasculature network throughout the tissue is achieved 
through the design and fabrication of the hollow tube structure in the micrometer 
scale. This hollow structure is also seeded with vascular cell types or angiogenic 
factors to promote the formation of functional microvascular networks structure, 
especially the branching that can size-up to the nanoscale range and also perme-
ation capability [51]. The two main additive manufacturing concepts used for vas-
cularized tissue formation are indirect and direct printing. In the indirect printing, 
a sacrificial material or negative mold is printed using thermo-reversible hydrogels 
such as Pluronic F-127 in combination with another material as the permanent scaf-
fold. Upon completion of the 3D printing, the sacrificial mold is removed to form 
the vascular network that was cellularized with vascular cells [52]. In the direct 
printing method, the vascular structure is actively printed either with cell-loaded 
biomaterial or cell-compatible bio-ink. The bio-ink utilized in this process normally 
has quick gelation/cross-linking ability, or extrinsically induced to crosslink/cured, 
to maintain a stable hollow structure [52].
3D bioprinting has been utilized to prepare vascular networks in several studies. 
Miller et al. printed a 3D carbohydrate-glass lattice that was late embedded within 
an engineered tissue with living cells. Then, the 3D carbohydrate-glass lattice is 
removed, leaving interconnected hollow structures that can be seeded with endo-
thelial cells to form the vasculature [53]. Later on, the same group of researchers 
proved that the vascular patch prepared using this technique can guide angiogenesis 
in vivo and rescue the ischemic tissues [54].
3.4 Other tissues
Besides the tissues discussed above, various other tissues have been and being 
fabricated with the still-evolving 3D bioprinting techniques. Many of these 3D 
printed tissues had also been implanted on patients as part of a clinical study [55–57] 
and systematic clinical trials are also being conducted for many of these products, 
which have been reviewed by Mehrotra et al. [58]. The 3D printed implants are in 
the clinical trial phase mostly as implants for an ankle injury, bone fracture, disease 
and deformation, and breast reconstruction. Among the other tissues that are in 
lab-scale fabrication and optimization but have a high potential for therapeutic 
use are liver tissue [59, 60], cardiac tissue [61, 62], kidney tissue [63, 64], pancreas 
tissue [65, 66], cartilage [67, 68], and neural tissues [69, 70].
Although the 3D bioprinting is a new technology, a few types of tissues produced 
by this technology are already utilized for therapeutic use. However, for the other 
tissues that have complex microarchitecture, and regulated by multiple signaling 
factors and cues from surrounding host tissues, it might need a longer time for the 
3D printed tissue substitutes to be used in the clinical setting. The 3D printing of 
complex tissues needs more synergistic research from researches in various fields 
and various angles before it could fully mimic the native tissue’s function. Another 
aspect to be considered will be the scaling up of the production using the clinical-
grade materials and commercial-scale 3D printers as most of the current studies are 
being done with experimental materials and lab-scale 3D printer technologies.
4. 3D bioprinting for personalized therapy
Personalized medicine, also known as precision medicine, is a concept in 
medicine that emphasizes that each patient should be managed differently based 
on an individual’s condition. This tailored therapy shall be able to provide the 
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best treatment plan for the patients to improve their prognosis. In personalized 
medicine, all the patient’s specific characteristics such as age, gender environment, 
height, weight, diet, environment, and genetics are being considered during the 
prevention, diagnosis, and treatment phase. Personalized medicine can improve the 
quality of patient care and reduce the cost by avoiding unnecessary diagnostic test-
ing and treatments [71–73]. Personalized medicine is not only limited to drugs but 
also for tissue engineering and regenerative medicine. Tissue engineering is highly 
personalized as a specific tissue-engineered substitute is needed for each patient. 
For example, different burn patients are presented with different degrees of injury 
and varied wound location, size, and dimension. Thus, a unique engineered skin 
needs to be prepared in the current good manufacturing practice (cGMP) facility 
for each patient.
3D bioprinting is one of the techniques that allow the preparation of personal-
ized tissue-engineered substitutes. One of the major advantages of 3D bioprinting 
in the field of tissue engineering is the possibility of producing personalized living 
tissue comprising of stem cells, cell-friendly matrix, and bioactive compound in 
the dimension uniquely suited for different patients. 3D bioprinting can be used to 
print simple living tissues like skin to a more complex hollow structure like a trachea 
and very complex organ like heart and kidney. This is something other living tissue 
fabrication techniques cannot achieve as these techniques do not allow precise 
deposition of cells at the space wanted. With the advances in the 3D bioprinting 
technology, nowadays, it is possible to print multiple types of cells, biomaterials, 
and bioactive compounds at different spaces to create a complex tissue that mimics 
the native tissue cellular arrangement and mechanical properties. Maturation of the 
3D printed tissues can be achieved using a bioreactor.
To prepare the personalized 3D bioprinted living tissue, the image of the tar-
geted tissue in specific patients needs to be taken and reconstructed into 3D, which 
will be used to guide the 3D printer to print the tissue in the dimension wanted 
layer-by-layer to form the 3D tissue [74]. Initially, 3D bioprinting is used to prepare 
engineered tissue in vitro, which can be transplanted in vivo afterward. However, 
it is difficult to maintain the shape and size of the engineered tissue in vitro. Thus, 
researchers come out with the idea of 3D bioprinting the tissue in situ, directly 
on the defect site (Figure 4). In situ 3D bioprinting allows the precise fitting of 
the printed tissue to the defect site, which is unique for every patient. In situ 3D 
bioprinting might be more efficient compared to the conventional technique as 
it allows more accurate reconstruction of defect sites and harnesses the natural 
healing capacity of the body to mature the printed tissue on time. An in situ 3D 
bioprinters can be as simple as a portable handheld spray gun to a complex robotic 
arm-assisted 3D bioprinter. Di Bella et al. developed an in situ handheld 3D bio-
printer that printed mesenchymal stem cells encapsulated within the hyaluronic 
acid methacrylate-gelatin methacrylamide hydrogel surrounded by the hyaluronic 
acid methacrylate-gelatin methacrylamide hydrogel + photoinitiator VA-086 shell, 
which can be photocured using the ultraviolet right for the treatment of cartilage 
defect [75]. Keriquel et al. used 3D bioprinted mesenchymal stem cells in collagen 
with hydroxyapatite for bone tissue engineering in a mice model [76]. Cohen et al. 
used a robot-assisted method of in situ 3D bioprinting for the deposition of alginate 
hydrogel and demineralized bone matrix-gelatin hydrogel for the regeneration of 
cartilage and bone defects, respectively [77].
Apart from personalized engineered tissue substitutes, 3D bioprinting also can 
be utilized for the preparation of personalized drug delivery systems and functional 
tissue models for personalized drug screening and disease modeling. Various models 
have been developed, including the liver [78], heart [79], blood vessel [80], skin [81], 
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skeletal muscle [82], and cancer [83]. The development of these models can greatly 
improve the medical care the patients will receive as distinctive prevention and treat-
ment strategies can be designed individually.
5.  3D bioprinting for developing in vitro tissue/organoid models  
for drug discovery
The invention of 3D bioprinting has revolutionized biomedical research and 
significant development in translational research closing the gap from bench to 
bedside. In the pharmaceutical industry, the value of 3D bioprinting is expected in 
lowering the attrition rate of a new drug since 3D bioprinting has the potential to 
precisely position multiple cell types as needed according to the tissue of interest 
(Figure 5). Thus, 3D bioprinting enables a more robust design of drug screening, 
drug delivery, high-throughput drug testing, and ADME assays. The application of 
3D bioprinting in the development of in vitro tissue or organoid models for drug 
discovery is discussed in this section.
5.1 Tumor or cancer model
The ability of 3D bioprinting in replicating tumor microenvironment (TME) 
provides a better model to assess drug response, tumor proliferation, and metas-
tasis. By 3D bioprinting, a tumor model with hypoxic core and necrosis could be 
recreated similar to the in vivo environment [84, 85]. The 3D-printed glioma model 
comprising of glioma stem cells incorporated in alginate/gelatin/fibrinogen bio-
ink is an example, and it showed higher resistance to temozolomide than in a 2D 
culture model [86]. Another case in point, fabrication of breast cancer model was 
achieved via the Organovo 3D NoveGen Bioprinter system where cancer cells are 
bordered with a stromal milieu of endothelial cells, fibroblast, and adipocytes. The 
said breast cancer model was viable for up to 14 days and possesses distinct internal 
compartmentalization. The model has been used to test hormonal drug response 
Figure 4. 
The personalized 3D bioprinted living tissue has been printed layer-by-layer to form the 3D tissue.
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and chemotherapeutic agents [87]. Most reports conclude that 3D bioprinting gave 
a higher effect be it tolerance or resistance to the drug tested as compared to the 
2D model of the disease, thus proving the value of 3D bioprinting in cancer drug 
screening.
5.2 Skin
The human skin’s inherent multi-layered, multicellular composition is in 
demand commercially for pharmaceutical and dermatological testing. Dermal 
skin equivalent has been successfully created using 3D bioprinting through several 
approaches. One of them is via direct cell printing of fibroblasts and keratinocytes 
in the collagen-based hydrogel to recreate the skin stratification [88]. The incor-
poration of melanocytes and fibroblasts in collagen/fibroblast bio-ink was also 
reported [89]. Maturation and stratification of 3D bioprinted skin construct could 
be achieved via exposure to the air-liquid interface as shown by Lee et al. with skin 
construct expressing skin-specific markers [90]. These skin-like constructs are 
of value in drug toxicity screening as shown by Tseng et al. where five different 
drugs, i.e. all-trans retinoic acid, dexamethasone, doxorubicin, 5′-fluorouracil, and 
forskolin, use their 3D bioprinted fibroblasts [91].
5.3 Cornea
Corneal in vitro/ex vivo model is desperately needed as cornea function as major 
barrier in penetration of drugs into eye; thus, drug absorption thru cornea need to 
be optimized for topical ocular drug application. Hence, many studies were done in 
an animal model which is not cost-effective. The complex arrangement of collagen 
lamellae could be recapitulated using a 3D bioprinting system. Such a corneal model 
has been successfully produced utilizing extrusion-based bioprinting (EBB) of colla-
gen/alginate/keratinocyte bio-ink [92]. Similar studies utilizing 3D bioprinting with 
Figure 5. 
The potential development of organoid models for drug discovery such as for cancer model, skin, cornea, 
intestines, muscle, cardiac tissue, and liver.
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a promising outcome have also been reported such as the generation of 3D multi-
lamellar silk film incorporated with human corneal stromal stem cells (hCSSCs). 
The silk film architecture supports the growth and differentiation of hCSSCs in 
producing matured corneal stroma with the desired optical and mechanical proper-
ties close to the native cornea [93].
5.4 Intestines
Drugs are commonly absorbed in the intestine; hence, an in vitro intestinal 
tissue model is of value in the early phase of drug screening. Such a model was 
fabricated successfully using the Organovo 3D NovoGen bioprinter system with 
epithelial cells and myofibroblast that has a polarized columnar epithelium with 
tight junctions and specialized cells that express cytochromes P450 (CYP450). The 
above said model is a good model for Crohn’s disease and internal bowel disease 
(IBD) that could be used in early-phase drug screening or toxicology study [94].
5.5 Muscle
Development of drugs that are delivered through intramuscular injection or 
for muscle injuries and muscular dystrophy require an in vitro muscle model for 
screening and testing. Alginate and Pluronic mixed with murine C2C12 cells have 
been successfully printed using the EBB method to create a 3D muscle construct 
that is used to screen several drugs and observe the cell viability, myogenic differen-
tiation, and tissue contractile force against the drug [95, 96].
5.6 Cardiac tissue
Cardiovascular disease (CVD) is the leading cause of death in the world. 
Cardiotoxicity is the primary cause of CVD drug retraction from the market and 
is often done in 2D cell cultures. Therefore, the development of cardiovascular 
disease modeling and drug screening platform is a necessity. Most work focuses 
on recreating the left ventricular myocardium where cardiac pathologies occur. A 
spontaneously and synchronously contracting tissue was successfully developed 
with aligning endothelial cells that are used for cardiotoxicity screening [97]. In 
another study, Lind et al. fabricated self-assembled rat-derived cardiac cells by 
direct printing of six functional bio-inks that are highly conductance, piezoresis-
tive, and biocompatible material. This model exhibits inotropic responses similar 
to isolated post-natal whole rat heart to several CVD drugs, i.e., L-type calcium 
channel blocker, verapamil, and β adrenergic agonist isoproterenol [98].
5.7 Liver
3D bioprinting approaches have been utilized in creating a liver disease model and 
liver tissue. Hepatotoxicity study of any drug introduced in the market is essential in 
any preclinical drug development. The establishment of in vitro liver models includes 
the incorporation of primary hepatocytes, hepatic cell lines, and stem cell-derived 
hepatic cells [99–101]. Kang et al. created a five-layer 3D hepatic structure using 
alginate and mouse induced hepatocyte-like cells that express albumin, ASGR1, and 
HNF4a [102]. Biomimetic liver tissue builds by Ma et al. showed better liver-specific 
function and drug metabolism potential compared to 2D monolayer culture [103].
The application of 3D bioprinting technology in the development of in vitro 
tissue or organoid models for drug discovery has fruitfully shown a better model in 
mitigating the risk associated with drug development. A 3D environment provides a 
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better representation of an in vivo model in addition to reducing or eliminating the 
use of animal model early in the drug development process. All in all, the reliable 
prediction of safety and efficacy means a significant reduction of time and financial 
investment of a particular drug in question.
6. Challenges of 3D printing in tissue engineering
Although tissue engineering emerged with this glory for a few decades, the 
initial attempts took way long [104], whereas 3D printing of complex biomaterials 
is a promising means of scaffold designing.
There are different types of 3D printers: laser-, inkjet-, and extrusion-based. 
However, inkjet-based is more popular in tissue engineering, where cells or bioma-
terials are incorporated into the substrate, as per digitally set instruction, to recreate 
a functional organ or tissue. Multiple printheads can be used in the case of organs/
tissue containing different types of cells. However, there are several challenges to 
address while designing a 3D printed engineered tissue [105].
6.1 Materials
6.1.1 Choice and processability of materials
The form of material input is important for this specialized process of 3D print-
ing. Hence, it is important to think through before choosing a material, whether it 
is compatible to form a filament or powder or pellet or solution, that is required for 
that process. Another important feature to be considered while choosing the mate-
rial is the expected mechanical strength of the scaffold and their biocompatibility 
and biodegradability.
6.1.2 Rate of biodegradation
The sole intent of engineered tissue is to replace and regenerate damaged tissue 
or organ. To comply with this requirement, the scaffold material of the transplanted 
tissue should be subject to remodeling and absorption. They should be able to 
degrade in equal or similar pace with the regeneration of extracellular matrix and 
differentiation of cells. This phenomenon depends on several factors, including 
hydrophilicity of the scaffold, surface area, porosity, degree of crystallinity, pres-
ence or absence of certain enzymes, etc. The most critical part here is harmoniza-
tion in these factors, so that the degradation of biomaterial and stress release to the 
surrounding tissue is well synchronized, to ensure healing of the damaged tissue.
6.1.3 Biodegradation of product
Biodegradation rate affects the cell viability and mobility, despite the general 
concept of this biodegradation being non-cytotoxic. The study finds that the fast 
degradation of the polymer may affect the cells negatively due to the formation of 
acidic byproduct. However, more research is required to support these data and to 
develop the degradation profile of the materials.
6.1.4 Mechanical strength
Cells are described to be sensitive toward the mechanical strength of the 
polymer scaffold. Rigid and non-flexible material may hinder the cytoskeleton 
13
3D Printed Bioscaffolds for Developing Tissue-Engineered Constructs
DOI: http://dx.doi.org/10.5772/intechopen.92418
assembly, cell organization, and receptor recruitment into “focal adhesion plaques,” 
which is crucial for cell signaling and anchoring. On the other hand, highly pli-
able material may not be able to provide the mechanical strength for anchoring or 
cytoskeleton assembly and thus affecting the cellular function as well.
6.2 Designing the polymer scaffold structure
6.2.1 Porosity
Different tissues require different porosities for the optimum effect. However, 
little knowledge is available. A general range of pore size is suggested to be consid-
ered for any type of cell, based on observations, rather than the established theory 
of optimum pore size for each cell type.
6.2.2 Morphology of the polymer scaffold
A study by Yin et al. describes that the microgrooves on the scaffold surface 
directly affect the cardiac function and susceptibility to arrhythmias [106]. This 
indicates the importance of the scaffold surface microenvironment, which posi-
tively or negatively affects the success of the tissue transplant.
6.2.3 Surface topography
It is stated that surface roughness may enhance adhesion between cell and extra-
cellular matrix. At the same time, too rough surface of the scaffold may exhaust the 
cell adhesion capability. On the other side, if the scaffold material is too sharp, the 
cells may get damaged. However, choosing a smooth surfaced scaffold material may 
require consideration of further modification or coating, as this feature does not 
facilitate cell adhesion.
6.3 Vascularization
Small and simpler organ printing has been successful, without much dif-
ficulty. However, it is not simple when comes to bigger and complex organ, due 
to difficulty in vascularization. Small tissues are avascular, and most of the time, 
aneural, alymphatic, and thin or hollow. They can receive nutrition from host 
vasculature. But when the transplanted tissue is thicker than 150–200 μm, oxygen 
cannot be diffused from host tissue to it. As such, to create a functional bigger 
and complex tissue or organ, an integrated vascular system is to be created, which 
is still not in place [105].
6.4 Cell seeding
The homogenous distribution of the cells throughout the scaffold is important 
for the effectivity of the tissue. The conventional usage of Petri dish may not be 
adequate to ensure the uniform seeding of these cells. The bioreactor technol-
ogy can influence a successful cell seeding, throughout the depth of the scaffold, 
evenly.
6.5 Future prospect of 3D printing
Despite all the challenges, 3D bioprinting offers great potential and diverse 
applications for the medical and healthcare sector.
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6.5.1 Complex organ engineering
Although few technical aspects are still to be figured out, rapid prototyping 
creates possibilities to generate complex organs like kidney, liver or even heart, 
despite having a heterogeneous cellular composition. With the fast pace of advance-
ment in technology and the number of researches going on in this field, the current 
challenges are expected to be resolved eventually. It has been foreseen that within 
20 years, 3D printed organs will be commercially available for transplantation [105].
6.5.2 In vivo test models
The animal study is a mandatory part of drug designing, which applies to tissue 
engineering and cell therapy. It has been estimated that about 115 million animals 
are being used in the biomedical industry per year [107]. The printed organs can 
replace these animal tests of safety, efficacy, and toxicology, saving a number of 
animals, and resolving the ethical conflict in this issue. At the same time, these 
printed organs can be more “close to the human subject” model than the animals.
6.5.3 New drug design
In an optimistic vision, it may be possible to have a printed piece of patient’s 
tissue to test which drug is suitable and effective for that particular patient, before 
applying on them, using this technology.
6.5.4 Mass production
Conventional tissue engineering involves customized scaffold preparation and 
manual cell seeding. Hence, the success rate is not consistent and the production 
cost is high, thereby resulting in very costly tissue that many people cannot afford. 
With the automation and advancement of bioreactor technique in conjunction with 
rapid prototyping, mass production of the complete organ is a very likely prospect 
[104]. This will increase the efficiency of the procedure of organ formation, and 
mass production capability will be economic and more affordable.
6.5.5 Less dependency on organ donation
The organ donation rate has always been far less than the requirement in a given 
period. On top of that, immunogenicity, rejection, and graft-versus-host disease 
make the transplantation process further difficult. With rapid prototyping, the 
scarcity of human organs can be resolved, with less immune rejection and higher 
effectivity.
6.5.6 In situ tissue printing
In situ generation of skin has already been achieved. With the progress of this 
technology, it is deemed that in future, a small piece of any tissue can be bioprinted 
in situ, during surgery, in no time, with precision [105].
7. Conclusions
Regenerative medicine is the new big thing in the medical and healthcare 
areas. Due to the promising outcome and compatibility for the human body, this 
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alternative treatment method might compete and/or take over conventional medi-
cine soon. Rapid prototyping has a very wide prospect in regenerative medicine, 
medical device, and pharmaceuticals. Incorporating the knowledge of cellular 
biology, biomaterial design, tissue engineering, bioreactors, and so on, organ regen-
eration will be much more precise and effective. With this speed of progression of 
science, the remaining challenges will be resolved soon, thereby opening a new era 
of healthcare and a better life for human beings.
Conflict of interest
The authors declare no conflict of interest.
© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
16
Design and Manufacturing
[1] Hull CW, Arcadia C. Apparatus 
for Production of Three-Dimensional 
Objects by Stereolithography. US Patent 
4575330; 1986
[2] Hoque ME, Hutmacher DW, 
Feng W, Li S, Huang MH, Vert M, et al. 
Fabrication using a rapid prototyping 
system and in vitro characterization 
of PEG-PCL-PLA scaffolds for 
tissue engineering. Journal of 
Biomaterials Science. Polymer Edition. 
2005;16(12):1595-1610
[3] Hoque ME, San WY, Wei F, Li S, 
Huang MH, Vert M, et al. Processing 
of polycaprolactone and 
polycaprolactone-based copolymers 
into 3D scaffolds, and their cellular 
responses. Tissue Engineering. Part A. 
2009;15(10):3013-3024
[4] Hoque ME, Meng TTH, Chuan YL, 
Chowdhury M, Prasad RGSV. 
Fabrication and characterization 
of hybrid PCL/PEG 3D scaffolds 
for potential tissue engineering 
applications. Materials Letters. 
2014;131:255-258
[5] Gioumouxouzis CI, Karavasili C,  
Fatouros DG. Recent advances in 
pharmaceutical dosage forms and 
devices using additive manufacturing 
technologies. Drug Discovery Today. 
2019;24(2):636-643
[6] Peng W, Datta P, Ayan B, Ozbolat V, 
Sosnoski D, Ozbolat IT. 3D bioprinting 
for drug discovery and development 
in pharmaceutics. Acta Biomaterialia. 
2017;57:26-46
[7] Ma X, Liu J, Zhu W, Tang M, 
Lawrence N, Yu C, et al. 3D bioprinting 
of functional tissue models for 
personalized drug screening and in vitro 
disease modeling. Advanced Drug 
Delivery Reviews. 2018;132:235-251
[8] Hoque ME. Robust formulation 
for the design of tissue engineering 
scaffolds: A comprehensive study on 
structural anisotropy, viscoelasticity 
and degradation of 3D scaffolds 
fabricated with customized desktop 
robot based rapid prototyping 
(DRBRP) system. Materials Science & 
Engineering. C, Materials for Biological 
Applications. 2017;72:433-443
[9] Hoque ME, Feng W, Wong YS, 
Hutmacher DW, Li S, Huang MH, et al. 
Scaffolds designed and fabricated with 
elastic biomaterials applying CAD-CAM 
technique. Tissue Engineering Parts A. 
2008;14:907
[10] Derakhshanfar S, Mbeleck R, 
Xu K, Zhang X, Zhong W, Xing M. 
3D bioprinting for biomedical devices 
and tissue engineering: A review of 
recent trends and advances. Bioactive 
Materials. 2018;3(2):144-156
[11] Dang TT, Nikkhah M, Memic A,  
Khademhosseini A. Polymeric 
biomaterials for implantable prostheses. 
In: Natural and Synthetic Biomedical 
Polymers. UK: Elsevier; 2014
[12] Hoang D, Perrault D, Stevanovic M, 
Ghiassi A. Surgical applications of 
three-dimensional printing: A review 
of the current literature & how to 
get started. Annals of Translational 
Medicine. 2016;4(23):456
[13] Okwuosa TC, Soares C, 
Gollwitzer V, Habashy R, Timmins P, 
Alhnan MA. On demand manufacturing 
of patient-specific liquid capsules 
via co-ordinated 3D printing 
and liquid dispensing. European 
Journal of Pharmaceutical Sciences. 
2018;118:134-143
[14] AlAli AB, Griffin MF, Butler PE. 
Three-dimensional printing surgical 
applications. Eplasty. 2015;15:e37
[15] Falchi M, Rollandi GA. CT of 




3D Printed Bioscaffolds for Developing Tissue-Engineered Constructs
DOI: http://dx.doi.org/10.5772/intechopen.92418
[16] Cheung CL, Looi T, Lendvay TS, 
Drake JM, Farhat WA. Use of 
3-dimensional printing technology and 
silicone modeling in surgical simulation: 
Development and face validation in 
pediatric laparoscopic pyeloplasty. 
Journal of Surgical Education. 
2014;71(5):762-767
[17] Cherkasskiy L, Caffrey JP, 
Szewczyk AF, Cory E, Bomar JD, 
Farnsworth CL, et al. Patient-specific 
3D models aid planning for triplane 
proximal femoral osteotomy in 
slipped capital femoral epiphysis. 
Journal of Children’s Orthopaedics. 
2017;11(2):147-153
[18] Zhang LG, Fisher JP, Leong KW, 
Starly B, Shirwaiker R. 3D bioprinting 
techniques. In: 3D Bioprinting and 
Nanotechnology in Tissue Engineering 
and Regenerative Medicine. UK: 
Elsevier; 2015
[19] Guvendiren M, Molde J, 
Soares RMD, Kohn J. Designing 
biomaterials for 3D printing. ACS 
Biomaterials Science & Engineering. 
2016;2(10):1679-1693
[20] Hutmacher DW, Hoque ME, 
Wong YS. Design, fabrication and 
physical characterization of scaffolds 
made from biodegradable synthetic 
polymers in combination with RP 
systems based on melt extrusion. In: 
Bidanda B, Bártolo P, editors. Virtual 
Prototyping & Bio Manufacturing in 
Medical Applications. USA: Springer 
Science+Business Media, LLC; 2008
[21] Cidonio G, Glinka M, Dawson JI,  
Oreffo ROC. The cell in the ink: 
Improving biofabrication by printing 
stem cells for skeletal regenerative 
medicine. Biomaterials. 2019;209:10-24
[22] Kačarević ŽP, Rider PM, Alkildani S, 
Retnasingh S, Smeets R, Jung O, et al. 
An introduction to 3D bioprinting: 
Possibilities, challenges and future 
aspects. Materials. 2018;11(11):2199
[23] You F, Eames BF, Chen X. 
Application of extrusion-based hydrogel 
bioprinting for cartilage tissue 
engineering. International Journal of 
Molecular Sciences. 2017;18(7):1597
[24] Murphy R, Walsh DP, 
Hamilton CA, Cryan SA, In Het 
Panhuis M, Heise A. Degradable 




[25] Lv CF, Zhu LY, Shi JP, Li ZA, 
Tang WL, Liu TT, et al. The fabrication 
of tissue engineering scaffolds by inkjet 
printing technology. Materials Science 
Forum. 2018;934:129-133
[26] Jammalamadaka U, Tappa K. Recent 
advances in biomaterials for 3D printing 
and tissue engineering. Journal of 
Functional Biomaterials. 2018;9(1):22
[27] Hoque ME, Chuan YL, 
Pashby I. Extrusion based rapid 
prototyping technique: An advanced 
platform for tissue engineering 
scaffold fabrication. Biopolymers. 
2012;97(2):83-93
[28] Bishop ES, Mostafa S, Pakvasa M, 
Luu HH, Lee MJ, Wolf JM, et al. 3-D 
bioprinting technologies in tissue 
engineering and regenerative medicine: 
Current and future trends. Genes and 
Diseases. 2017;4(4):185-195
[29] Skardal A, Atala A. Biomaterials 
for integration with 3-D bioprinting. 
Annals of Biomedical Engineering. 
2015;43(3):730-746
[30] Cui H, Nowicki M, Fisher JP, 
Zhang LG. 3D bioprinting for organ 
regeneration. Advanced Healthcare 
Materials. 2017;6(1):1601118
[31] Ahangar P, Cooke ME, Weber MH, 
Rosenzweig DH, Ahangar P, Cooke ME, 
et al. Current biomedical applications 
of 3D printing and additive 
Design and Manufacturing
18
manufacturing. Applied Sciences. 
2019;9(8):1713
[32] Tappa K, Jammalamadaka U. Novel 
biomaterials used in medical 3D 
printing techniques. Journal of 
Functional Biomaterials. 2018;9(1):17
[33] Ahlfeld T, Cidonio G, Kilian D, 
Duin S, Akkineni AR, Dawson JI, et al. 
Development of a clay based bioink for 
3D cell printing for skeletal application. 
Biofabrication. 2017;9(3):034103
[34] Zhang YS, Yue K, Aleman J, 
Mollazadeh-Moghaddam K, Bakht SM, 
Yang J, et al. 3D bioprinting for tissue and 
organ fabrication. Annals of Biomedical 
Engineering. 2017;45(1):148-163
[35] Moroni L, Burdick JA, Highley C, 
Lee SJ, Morimoto Y, Takeuchi S, et al. 
Biofabrication strategies for 3D in vitro 
models and regenerative medicine. 
Nature Reviews Materials. 
2018;3(5):21-37
[36] You S, Li J, Zhu W, Yu C, Mei D,  
Chen S. Nanoscale 3D printing of 
hydrogels for cellular tissue engineering. 
Journal of Materials Chemistry B. 
2018;6(15):2187-2197
[37] Donderwinkel I, van Hest JCM,  
Cameron NR. Bio-inks for 3D 
bioprinting: Recent advances and 
future prospects. Polymer Chemistry. 
2017;8(31):4451-4471
[38] Maiullari F, Costantini M, Milan M, 
Pace V, Chirivì M, Maiullari S, et al. A 
multi-cellular 3D bioprinting approach 
for vascularized heart tissue engineering 
based on HUVECs and iPSC-derived 
cardiomyocytes. Scientific Reports. 
2018;8(1):13532
[39] Park JY, Shim J-H, Choi S-A, 
Jang J, Kim M, Lee SH, et al. 3D 
printing technology to control BMP-2 
and VEGF delivery spatially and 
temporally to promote large-volume 
bone regeneration. Journal of Materials 
Chemistry B. 2015;3(27):5415-5425
[40] Oh K-J, Yu HS, Park J, Lee H-S, 
Park SA, Park K. Co-culture of smooth 
muscle cells and endothelial cells 
on three-dimensional bioprinted 
polycaprolactone scaffolds for 
cavernosal tissue engineering. The 
Aging Male. 2019;1-6
[41] Popov VV, Muller-Kamskii G, 
Kovalevsky A, Dzhenzhera G, 
Strokin E, Kolomiets A, et al. Design 
and 3D-printing of titanium bone 
implants: Brief review of approach and 
clinical cases. Biomedical Engineering 
Letters. 2018;8(4):337-344
[42] Bose S, Vahabzadeh S, 
Bandyopadhyay A. Bone tissue 
engineering using 3D printing. Materials 
Today. 2013;16(12):496-504
[43] Sachs E, Cima M, Cornie J. Three-
dimensional printing: Rapid tooling and 
prototypes directly from a CAD model. 
CIRP Annals. 1990;39(1):201-204
[44] Goriainov V, McEwan JK, 
Oreffo ROC, Dunlop DG. Application 
of 3D-printed patient-specific skeletal 
implants augmented with autologous 
skeletal stem cells. Regenerative 
Medicine. 2018;13(3):283-294
[45] Shahrokhi S, Arno A, 
Jeschke MG. The use of dermal 
substitutes in burn surgery: Acute 
phase. Wound Repair and Regeneration. 
2014;22(1):14-22
[46] Varkey M, Visscher DO, van 
Zuijlen PPM, Atala A, Yoo JJ. Skin 
bioprinting: The future of burn wound 
reconstruction? Burns & Trauma. 
2019;7(1):4
[47] Tarassoli SP, Jessop ZM, Al-Sabah A, 
Gao N, Whitaker S, Doak S, et al. Skin 
tissue engineering using 3D bioprinting: 
An evolving research field. Journal of 
Plastic, Reconstructive & Aesthetic 
Surgery. 2018;71(5):615-623
[48] Albanna M, Binder KW, Murphy SV, 
Kim J, Qasem SA, Zhao W, et al. In situ 
19
3D Printed Bioscaffolds for Developing Tissue-Engineered Constructs
DOI: http://dx.doi.org/10.5772/intechopen.92418
bioprinting of autologous skin cells 
accelerates wound healing of extensive 
excisional full-thickness wounds. 
Scientific Reports. 2019;9(1):1856
[49] Jain RK, Au P, Tam J, Duda DG, 
Fukumura D. Engineering vascularized 
tissue. Nature Biotechnology. 
2005;23(7):821
[50] Jaklenec A, Stamp A, Deweerd E, 
Sherwin A, Langer R. Progress in the 
tissue engineering and stem cell industry 
“are we there yet?”. Tissue Engineering. 
Part B, Reviews. 2012;18(3):155-166
[51] Richards D, Jia J, Yost M, 
Markwald R, Mei Y. 3D bioprinting 
for vascularized tissue fabrication. 
Annals of Biomedical Engineering. 
2017;45(1):132-147
[52] Kolesky DB, Homan KA, 
Skylar-Scott MA, Lewis JA. Three-
dimensional bioprinting of thick 
vascularized tissues. Proceedings of 
the National Academy of Sciences 
of the United States of America. 
2016;113(12):3179-3184
[53] Miller JS, Stevens KR, Yang MT, 
Baker BM, Nguyen D-HT, Cohen DM, 
et al. Rapid casting of patterned 
vascular networks for perfusable 
engineered three-dimensional tissues. 
Nature Materials. 2012;11:768
[54] Mirabella T, MacArthur JW, 
Cheng D, Ozaki CK, Woo YJ, Yang MT, 
et al. 3D-printed vascular networks 
direct therapeutic angiogenesis 
in ischaemia. Nature Biomedical 
Engineering. 2017;1:83
[55] Morrison RJ, Hollister SJ, 
Niedner MF, Mahani MG, Park AH, 
Mehta DK, et al. Mitigation of 
tracheobronchomalacia with 3D-printed 
personalized medical devices in 
pediatric patients. Science Translational 
Medicine. 2015;7(285):285ra64
[56] Kim D, Lim J-Y, Shim K-W, 
Han JW, Yi S, Yoon DH, et al. Sacral 
reconstruction with a 3D-printed 
implant after hemisacrectomy in a 
patient with sacral osteosarcoma: 1-year 
follow-up result. Yonsei Medical Journal. 
2017;58(2):453-457
[57] Wu A-M, Lin J-L, Kwan KYH, Wang 
X-Y, Zhao J. 3D-Printing techniques in 
spine surgery: The future prospects and 
current challenges. Expert Review of 
Medical Devices. 2018;15(6):399-401
[58] Mehrotra S, Moses JC, 
Bandyopadhyay A, Mandal BB. 3D 
printing/bioprinting based tailoring of 
in vitro tissue models: Recent advances 
and challenges. ACS Applied Bio 
Materials. 2019;2(4):1385-1405
[59] Nguyen D, Robbins J, Crogan- 
Grundy C, Gorgen V, Bangalore P,  
Perusse D, et al. Functional 
characterization of three-dimensional 
(3D) human liver tissues generated 
by an automated bioprinting 
platform. The FASEB Journal. 
2015;29(1_supplement):LB424
[60] Skeldon G, Lucendo-Villarin B, 
Shu W. Three-dimensional bioprinting 
of stem-cell derived tissues for human 
regenerative medicine. Philosophical 
Transactions of the Royal Society B. 
2018;373(1750):20170224
[61] Lee A, Feinberg AW. 3D 
bioprinting of cardiac muscle tissue. 
In: 3D Bioprinting in Regenerative 
Engineering. USA: CRC Press; 2018. 
p. 247-268
[62] Liu J, He J, Liu J, Ma X, Chen Q , 
Lawrence N, et al. Rapid 3D bioprinting 
of in vitro cardiac tissue models 
using human embryonic stem cell-
derived cardiomyocytes. Bioprinting. 
2019;13:e00040
[63] Turunen S, Kaisto S, Skovorodkin I, 
Mironov V, Kalpio T, Vainio S, et al. 
3D bioprinting of the kidney—Hype 




[64] Subramanian B, Rudym D, 
Cannizzaro C, Perrone R, Zhou J, 
Kaplan DL. Tissue-engineered three-
dimensional in vitro models for 
normal and diseased kidney. 
Tissue Engineering. Part A. 
2010;16(9):2821-2831
[65] Kim J, Shim IK, Hwang DG, Lee YN, 
Kim M, Kim H, et al. 3D cell printing 
of islet-laden pancreatic tissue-derived 
extracellular matrix bioink constructs 
for enhancing pancreatic functions. 
Journal of Materials Chemistry B. 
2019;7(10):1773-1781
[66] Lee SJ, Lee JB, Park Y-W, Lee DY. 3D 
bioprinting for artificial pancreas organ. 
Advances in Experimental Medicine and 
Biology. 2018;1064:355-374
[67] Jung CS, Kim BK, Lee J, Min B-H, 
Park S-H. Development of printable 
natural cartilage matrix bioink for 3D 
printing of irregular tissue shape. Tissue 
Engineering and Regenerative Medicine. 
2018;15(2):155-162
[68] Lipskas J, Deep K, Yao W. Robotic-
assisted 3D bio-printing for repairing 
bone and cartilage defects through a 
minimally invasive approach. Scientific 
Reports. 2019;9(1):3746
[69] Zhu W, Tringale KR, Woller SA, 
You S, Johnson S, Shen H, et al. Rapid 
continuous 3D printing of customizable 
peripheral nerve guidance conduits. 
Materials Today. 2018;21(9):951-959
[70] Petcu EB, Midha R, McColl E, 
Popa-Wagner A, Chirila TV, Dalton PD. 
3D printing strategies for peripheral 
nerve regeneration. Biofabrication. 
2018;10(3):32001
[71] Vogenberg FR, Isaacson Barash C, 
Pursel M. Personalized medicine:  
Part 1: Evolution and development 
into theranostics. Physical Therapy. 
2010;35(10):560-576
[72] Duffy DJ. Problems, challenges and 
promises: Perspectives on precision 
medicine. Briefings in Bioinformatics. 
2015;17(3):494-504
[73] Ginsburg GS, Phillips KA. Precision 
medicine: From science to value. Health 
Affairs. 2018;37(5):694-701
[74] Li X, Liu L, Zhang X, Xu T. Research 
and development of 3D printed 
vasculature constructs. Biofabrication. 
2018;10(3):32002
[75] Di Bella C, Duchi S, O’Connell CD, 
Blanchard R, Augustine C, Yue Z, et al. 
In situ handheld three-dimensional 
bioprinting for cartilage regeneration. 
Journal of Tissue Engineering 
and Regenerative Medicine. 
2018;12(3):611-621
[76] Keriquel V, Oliveira H, Rémy M, 
Ziane S, Delmond S, Rousseau B, et al. 
In situ printing of mesenchymal stromal 
cells, by laser-assisted bioprinting, for 
in vivo bone regeneration applications. 
Scientific Reports. 2017;7(1):1778
[77] Cohen DL, Lipton JI, Bonassar LJ, 
Lipson H. Additive manufacturing forin 
siturepair of osteochondral defects. 
Biofabrication. 2010;2(3):35004
[78] Witowski JS, Pędziwiatr M, 
Major P, Budzyński A. Cost-effective, 
personalized, 3D-printed liver model 
for preoperative planning before 
laparoscopic liver hemihepatectomy 
for colorectal cancer metastases. 
International Journal of Computer 
Assisted Radiology and Surgery. 
2017;12(12):2047-2054
[79] Lau IWW, Liu D, Xu L, Fan Z, 
Sun Z. Clinical value of patient-specific 
three-dimensional printing of 
congenital heart disease: Quantitative 
and qualitative assessments. PLoS One. 
2018;13(3):e0194333
[80] Schöneberg J, De Lorenzi F, Theek B, 
Blaeser A, Rommel D, Kuehne AJC, 
et al. Engineering biofunctional in vitro 
vessel models using a multilayer 
21
3D Printed Bioscaffolds for Developing Tissue-Engineered Constructs
DOI: http://dx.doi.org/10.5772/intechopen.92418
bioprinting technique. Scientific 
Reports. 2018;8(1):10430
[81] Kim BS, Lee J-S, Gao G, Cho 
D-W. Direct 3D cell-printing of human 
skin with functional transwell system. 
Biofabrication. 2017;9(2):25034
[82] Berry DB, You S, Warner J, 
Frank LR, Chen S, Ward SR. A 3D 
tissue-printing approach for validation 
of diffusion tensor imaging in skeletal 
muscle. Tissue Engineering. Part A. 
2017;23(17-18):980-988
[83] Bourland J, Fradette J, Auger FA. 
Tissue-engineered 3D melanoma model 
with blood and lymphatic capillaries for 
drug development. Scientific Reports. 
2018;8(1):13191
[84] Albritton JL, Miller JS. 3D 
bioprinting: Improving in vitro models 
of metastasis with heterogeneous tumor 
microenvironments. Disease Models & 
Mechanisms. 2017;10(1):3-14
[85] Zhang YS, Duchamp M, 
Oklu R, Ellisen LW, Langer R, 
Khademhosseini A. Bioprinting the 
cancer microenvironment. ACS 
Biomaterials Science & Engineering. 
2016;2(10):1710-1721
[86] Dai X, Ma C, Lan Q , Xu T. 3D 
bioprinted glioma stem cells for brain 
tumor model and applications of 
drug susceptibility. Biofabrication. 
2016;8(4):045005
[87] King SM, Presnell SC, Nguyen DG. 
Abstract 2034: Development of 3D 
bioprinted human breast cancer for in 
vitro drug screening. Cancer Research. 
2014;74(Suppl 19):2034-2034
[88] Bakhtiar SM, Butt HA, Zeb S, 
Quddusi DM, Gul S, Dilshad E. 3D 
printing technologies and their 
applications in biomedical science. 
In: Omics Technologies and Bio-
Engineering: Towards Improving 
Quality of Life. UK: Elsevier; 2017
[89] Min D, Lee W, Bae IH, Lee TR,  
Croce P, Yoo SS. Bioprinting 
of biomimetic skin containing 
melanocytes. Experimental 
Dermatology. 2018;27(5):453-459
[90] Lee V, Singh G, Trasatti JP, 
Bjornsson C, Xu X, Tran TN, et al. 
Design and fabrication of human skin 
by three-dimensional bioprinting. 
Tissue Engineering. Part C, Methods. 
2014;20(6):473-484
[91] Tseng H, Gage JA, Shen T, 
Haisler WL, Neeley SK, Shiao S, et al. A 
spheroid toxicity assay using magnetic 
3D bioprinting and real-time mobile 
device-based imaging. Scientific 
Reports. 2015;5:13987-13987
[92] Isaacson A, Swioklo S, Connon CJ. 
3D bioprinting of a corneal stroma 
equivalent. Experimental Eye Research. 
2018;173:188-193
[93] Ghezzi CE, Marelli B, 
Omenetto FG, Funderburgh JL, 
Kaplan DL. 3D functional corneal 
stromal tissue equivalent based on 
corneal stromal stem cells and multi-
layered silk film architecture. PLoS One. 
2017;12(1):e0169504-e0169504
[94] Madden LR, Nguyen TV, 
Garcia-Mojica S, Shah V, Le AV, Peier A, 
et al. Bioprinted 3D primary human 
intestinal tissues model aspects of native 
physiology and ADME/Tox functions. 
iScience. 2018;2:156-167
[95] Mozetic P, Giannitelli SM, Gori M, 
Trombetta M, Rainer A. Engineering 
muscle cell alignment through 3D 
bioprinting. Journal of Biomedical 
Materials Research Part A. 2017;105(9): 
2582-2588
[96] Chen S, Nakamoto T, Kawazoe N, 
Chen G. Engineering multi-layered 
skeletal muscle tissue by using 3D 




[97] Zhang YS, Arneri A, Bersini S, 
Shin SR, Zhu K, Goli-Malekabadi Z, 
et al. Bioprinting 3D microfibrous 
scaffolds for engineering 
endothelialized myocardium and heart-
on-a-chip. Biomaterials. 2016;110:45-59
[98] Lind JU, Busbee TA, Valentine AD,  
Pasqualini FS, Yuan H, Yadid M,  
et al. Instrumented cardiac 
microphysiological devices via 
multimaterial three-dimensional 
printing. Nature Materials. 
2017;16(3):303-308
[99] Guguen-Guillouzo C, Corlu A,  
Guillouzo A. Stem cell-derived 
hepatocytes and their use in toxicology. 
Toxicology. 2010;270(1):3-9
[100] Hewitt NJ, Lechón MJG, 
Houston JB, Hallifax D, Brown HS, 
Maurel P, et al. Primary hepatocytes: 
Current understanding of the 
regulation of metabolic enzymes 
and transporter proteins, and 
pharmaceutical practice for the 
use of hepatocytes in metabolism, 
enzyme induction, transporter, 
clearance, and hepatotoxicity 
studies. Drug Metabolism Reviews. 
2007;39(1):159-234
[101] Khetani SR, Bhatia SN. Microscale 
culture of human liver cells for drug 
development. Nature Biotechnology. 
2008;26(1):120-126
[102] Kang K, Kim Y, Jeon H, 
Lee SB, Kim JS, Park SA, et al. Three-
dimensional bioprinting of 
hepatic structures with directly 
converted hepatocyte-like cells. 
Tissue Engineering. Part A. 
2018;24(7-8):576-583
[103] Ma X, Qu X, Zhu W, Li Y-S, 
Yuan S, Zhang H, et al. Deterministically 
patterned biomimetic human iPSC-
derived hepatic model via rapid 
3D bioprinting. Proceedings of 
the National Academy of Sciences 
of the United States of America. 
2016;113(8):2206-2211
[104] Mironov V, Boland T, Trusk T, 
Forgacs G, Markwald RR. Organ 
printing: Computer-aided jet-based 
3D tissue engineering. Trends in 
Biotechnology. 2003;21(4):157-161
[105] Ventola CL. Medical applications 
for 3D printing: Current and 
projected uses. Physical Therapy. 
2014;39(10):704-711
[106] Yin L, Bien H, Entcheva E. Scaffold 
topography alters intracellular calcium 
dynamics in cultured cardiomyocyte 
networks. American Journal of 
Physiology-Heart and Circulatory 
Physiology. 2004;287(3):H1276-85
[107] Rai J, Kaushik K. Reduction 
of animal sacrifice in biomedical 
science & research through alternative 
design of animal experiments. 
Saudi Pharmaceutical Journal. 
2018;26(6):896-902
